Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis
Recruitment status was Recruiting
An open-label study to evaluate the efficacy and safety of orally administered Tamibarotene to patients of Lupus Nephritis
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
- Renal Function [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- Urinary Protein values [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- Urinary Sediment [ Time Frame: 28 weeks ] [ Designated as safety issue: No ]
- Anti di-DNA antibody and complement C3 [ Time Frame: 28 weeks ] [ Designated as safety issue: No ]
- Disease activity index, total improvement [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- SLEDAI [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- Safety [ Time Frame: 28 weeks ] [ Designated as safety issue: Yes ]
|Study Start Date:||September 2010|
|Estimated Study Completion Date:||February 2013|
|Estimated Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
Tamibarotene is a synthetic retinoid presently approved in Japan for the treatment of APL, and in US, Europe and China it is still under development for APL. Compared to other retinoid drugs available, Tamibarotene has not just a higher activity as a retinoid, but also shows a higher receptor selectivity towards the Retinoic Acid Receptor (RAR) subtypes alfa and beta, but not gamma. All trans retinoic acid (ATRA) and its derivatives are usually pan-agonists to these subtypes, and often are know for the irritation to the skin as one of their major side effects which is due to the RAR gamma subtype. Moreover, unlike ATRA tamibarotene does not cause induction of drug metabolism by CRABP.
Tamibarotene is known to moderate T1/T2 balance as well as Treg/Th17 balance through binding RAR-alfa receptor, and shows efficacy to various autoimmune and inflammatory animal models.
In the preliminary clinical research, patients with lupus nephritis for whom prednisolone treatment was not sufficient enough was treated with oral administration of ATRA to show a remarkable decrease in their protein urea (ref. Kinoshita et al, Am.J.Kidney Dis., 2009 Jul 21).
Based on these results, the investigators plan by this study to evaluate the efficacy of tamibarotene together with the safety to the patients of lupus nephritis.
Tamibarotene is used clinically in Japan since 2005. It's side effects are known to be similar to that of other clinically used retinoids.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01226147
|Contact: Masanori Funauchi, M.D.||+email@example.com|
|Kinki University Hospital||Recruiting|
|Osaka, Japan, 5898511|
|Contact: Masanori Funauchi, M.D. firstname.lastname@example.org|
|Principal Investigator: Masanori Funauchi, M.D.|